Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cannabidiol (CBD) oral solution Clear all
Terminated Phase 2 Interventional Results available

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome

NCT03458416
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

NCT02953548
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 27, 2026, 9:22 AM EDT
Active, not recruiting Phase 4 Interventional

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

NCT05044819
View directory record Official record
Conditions
Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Interventions
Cannabidiol
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Little Rock, Arkansas • Downey, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 27, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

NCT02551731
View directory record Official record
Conditions
Spasms, Infantile
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
6 Months to 36 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 27, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628
View directory record Official record
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabidiol Effects on Blood Alcohol Level and Intoxication

NCT06105138
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
200mg Cannabidiol oral solution, 30mg Cannabidiol oral solution, Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
21 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 27, 2026, 9:22 AM EDT
Recruiting Phase 3 Interventional

Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

NCT07123467
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Anxiety Disorders
Interventions
Low-Dose Cannabidiol, Placebo Matched to Moderate-Dose Cannabidiol, Moderate-Dose Cannabidiol, Placebo Matched to Low-Dose Cannabidiol
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Results available

Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer

NCT04428203
View directory record Official record
Conditions
Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma
Interventions
Epidiolex Oral Liquid Product
Drug
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia

NCT03941288
View directory record Official record
Conditions
Gastroparesis, Dyspepsia
Interventions
Cannabidiol, placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544750
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

NCT04978428
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder), Tourette Syndrome, Hoarding Disorder
Interventions
Cannabidiol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Results available

University of Alabama at Birmingham (UAB) Pediatric CBD Program

NCT02695537
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Epidiolex
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 19 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 27, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty

NCT06234631
View directory record Official record
Conditions
Knee Replacement Surgery, Osteoarthritis, Knee
Interventions
Epidiolex oral solution, Placebo
Drug · Other
Lead sponsor
Chad Brummett
Other
Eligibility
18 Years to 80 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Oral Cannabidiol for Opioid Withdrawal

NCT04238754
View directory record Official record
Conditions
Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 27, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 27, 2026, 9:22 AM EDT
Withdrawn Phase 2 Interventional

CBD for Sleep in People With HIV

NCT05097651
View directory record Official record
Conditions
Sleep Disturbance
Interventions
Cannabidiol oral solution, Inert sesame seed oil
Drug
Lead sponsor
Mariana Cherner, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cannabidiol and CES1 Interactions in Healthy Subjects

NCT04603391
View directory record Official record
Conditions
Drug Interaction
Interventions
dl-Methylphenidate plus Cannabidiol, dl-Methylphenidate plus Cannabidiol Placebo solution
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 27, 2026, 9:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

NCT07298408
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Interventions
Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution
Drug
Lead sponsor
Florida A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 27, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome

NCT07778810
View directory record Official record
Conditions
Sturge - Weber Syndrome (SWS)
Interventions
Epidiolex 100 mg/mL Oral Solution
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Month to 18 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 27, 2026, 9:22 AM EDT
Recruiting Phase 3 Interventional

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

NCT04411225
View directory record Official record
Conditions
Early Psychosis
Interventions
Cannabidiol oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
16 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).

NCT04721691
View directory record Official record
Conditions
Electrical Status Epilepticus of Slow-Wave Sleep
Interventions
Epidiolex 100 mg/mL Oral Solution, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

NCT05600114
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Cannabidiol oral solution, Placebo
Drug
Lead sponsor
EmpowerPharm Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Encino, California • Lemon Grove, California • Los Alamitos, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 27, 2026, 9:22 AM EDT
Withdrawn Not applicable Interventional

Effects of CBD Oil on Memory Reconsolidation and Trauma-Related Symptoms

NCT05892276
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Trauma Memory Reactivation, Cannabidiol (CBD) Broad-Spectrum Oil, Placebo Oil
Behavioral · Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 27, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224690
View directory record Official record
Conditions
Epilepsy, Lennox-Gastaut Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 27, 2026, 9:22 AM EDT